Spyre Therapeutics, Inc.
SYRE
Kedudukan dalam Saham
#2336
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical... Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Harga Saham
$91.87
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$8.48B
Perubahan (1 hari)
8.44%
Perubahan (1 tahun)
295.14%
Negara
US
Perdagangan Spyre Therapeutics, Inc. (SYRE)
Kategori
Healthcare
Pendapatan untuk Spyre Therapeutics, Inc. (SYRE)
Pendapatan pada Jun 2026 TTM: $-178.92M
Menurut laporan kewangan terkini Spyre Therapeutics, Inc., pendapatan semasa syarikat ialah $-178.92M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-338.82M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-83.95M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Spyre Therapeutics, Inc. dari 2014 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-178.92M | -13.97% |
| 2024 | $-207.97M | -38.62% |
| 2023 | $-338.82M | 303.59% |
| 2022 | $-83.95M | 27.86% |
| 2021 | $-65.66M | -18.83% |
| 2020 | $-80.89M | 3.37% |
| 2019 | $-78.25M | 76.45% |
| 2018 | $-44.35M | 62.83% |
| 2017 | $-27.24M | 25.52% |
| 2016 | $-21.70M | 92.10% |
| 2015 | $-11.30M | 9.16% |
| 2014 | $-10.35M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -3,048.22% |
US
|
|
| $-3.09B | 1,625.37% |
US
|
|
| $-4.02B | 2,144.71% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,190.25% |
NL
|
